Evidence map›Paper›PMID 42003043›Full record

ArticleJournal of surgical oncology2026

Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Melanoma: Assessing Clinical Value in a Cohort Over 1000 Patients.

Daniela Duarte-Bateman, Alan Shen, Yanwen Chen, Jorge Arpi-Palacios, Eduardo Williams, Viren Patel, Rebecca Knackstedt, Brian R Gastman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniela Duarte-BatemanDepartment of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-7628-4113
Alan ShenCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
Yanwen ChenLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Jorge Arpi-PalaciosDepartment of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-3310-9646
Eduardo WilliamsCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
Viren PatelDepartment of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
Rebecca KnackstedtDepartment of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
Brian R GastmanDepartment of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe sentinel lymph node biopsy (SLNB) remains the standard for identifying micrometastasis in melanoma. In this study, we utilized our prospectively maintained database to assess whether adding indocyanine green (ICG) fluorescence imaging to radioisotope lymphoscintigraphy improved sentinel node detection and, consequently, clinical outcomes.

methodsConsecutive patients with cutaneous melanoma who underwent dual technique SLNB by the senior author (B.R.G.) from 2012 to 2022 were enrolled. All patients with a negative SLNB result were subjected to a minimum follow-up period of 12 months. Positive and false-negative rates were calculated, and recurrence-free survival (RFS) was used as a measure of clinical outcomes.

resultsA total of 1267 patients were identified. The average age was 62 years, with 526 females (41.6%). The mean Breslow depth was 1.82 mm (range 0.2-24 mm). Among 3403 SLNs sampled, 358 were positive (91.1% identified by both modalities). The false-negative rate was 8.5% (25/293), and the median time to recurrence was 13.7 months (range: 2.8-60.4 months). The 12-month RFS for stages IA-IIC were 99%, 98%, 95%, 97%, and 84%, respectively (p = 0.016).

conclusionsThese findings support the use of an ICG-based dual technique in SLNB for melanoma, demonstrating diagnostic precision with excellent patient outcomes.

Indexed as

Indocyanine GreenMelanomaSentinel Lymph Node BiopsySkin NeoplasmsAdultAgedAged, 80 and overColoring AgentsCutaneous Malignant MelanomaFemaleFollow-Up StudiesHumansLymphatic MetastasisLymphoscintigraphyMaleMiddle AgedColoring AgentsIndocyanine Greenindocyanine greenmelanomarecurrence‐free survivalsentinel lymph node biopsy

Identifiers

PMID42003043
PMCPMC13353130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.